Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Easyderm is a brand name primarily associated with topical formulations of clobetasol propionate, a super-high potency (Group I) corticosteroid used for the treatment of severe inflammatory skin conditions. It is indicated for the relief of pruritic and inflammatory manifestations of corticosteroid-responsive dermatoses, such as psoriasis, recalcitrant eczemas, and lichen planus. Clobetasol propionate functions as an agonist of the glucocorticoid receptor; upon binding, it translocates to the nucleus where it modulates gene expression, leading to the induction of lipocortins. These proteins inhibit phospholipase A2, thereby blocking the release of arachidonic acid and the subsequent synthesis of inflammatory mediators like prostaglandins and leukotrienes. This mechanism results in potent anti-inflammatory, antipruritic, and vasoconstrictive actions. It is important to note that Easyderm is also a prominent brand for hydrocolloid wound dressings manufactured by Daewoong Pharmaceutical, which are classified as medical devices rather than pharmaceutical drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Easyderm.